Evaluating Cost-Effectiveness: An Essential Part of New Cancer Drug Approvals
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- October 2017
has subject area
- 1102 Cardiorespiratory Medicine and Haematology (FoR)
- 1103 Clinical Sciences (FoR)
- 1112 Oncology and Carcinogenesis (FoR)
- Cost-Benefit Analysis (MeSH)
- Drug Approval (MeSH)
- Humans (MeSH)
- Lung Neoplasms (MeSH)
- Oncology & Carcinogenesis (Science Metrix)
- United States Food and Drug Administration (MeSH)
published in
- Journal of Thoracic Oncology Journal